Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.

Parikh, P M; Shah, S R; Shah, S C; Sheth, V; Patel, R A; Shah, K C; Jain, P K

Parikh, P M; Shah, S R; Shah, S C; Sheth, V; Patel, R A; Shah, K C; Jain, P K.

Indian J Cancer ; 1996 Mar; 33(1): 17-20

Article in English | IMSEAR | ID: sea-50995

ABSTRACT

ABSTRACT

Ondansetron was used as an antiemetic along with dexamethasone during 16 cycles of highly or moderately ematogenic chemotherapy. There was major control in two cycles and complete control in the remaining 14. Side effects were minor and did not require discontinuation of the drug. This combination, therefore, appears to be safe and effective in preventing chemotherapy induced emesis.

Subject(s)

Adult; Antiemetics/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Dexamethasone/adverse effects; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ondansetron/adverse effects; Receptors, Serotonin/drug effects; Receptors, Serotonin, 5-HT3; Serotonin Antagonists/adverse effects; Vomiting/prevention & control

Fulltext

XML

Search on Google

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Serotonin Antagonists / Vomiting / Female / Humans / Male / Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Receptors, Serotonin / Ondansetron / Adult Language: English Journal: Indian J Cancer Year: 1996 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google